Claravant Analytics LLC's advisory board comprises 11 people, many with both industry experience and at least five years of experience working at FDA. The board has been helping to build out the firm's network of over 75 experts, which will evaluate and rate biotech programs. Sources: Claravant and other company websites, LinkedIn     


FDA and industry experience

David Feigal

2008-10: VP global regulatory strategy at Amgen Inc. (NASDAQ:AMGN); 2006-07: SVP global safety and regulatory at Elan Corp. plc.; 1992-2004: at FDA - director, Center for Devices & Radiological Health (CDRH); director, Division of Anti-Infective and Antiviral Drug Products, Center for Drug Evaluation & Research (CDER); deputy director, Center for Biologics Evaluation & Research (CBER)